We are live on
!
Find out more
DJYG
David J. Yvars Group Portfolio holdings
AUM
$212M
1-Year Est. Return
33.06%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+33.06%
3 Year Est. Return
+125.45%
5 Year Est. Return
+204.83%
10 Year Est. Return
–
AUM
$79.8M
AUM Growth
-$10.2M
(-11%)
Cap. Flow
-$16M
Cap. Flow
% of AUM
-20.05%
Top 10 Holdings %
Top 10 Hldgs %
65.61%
Holding
71
New
5
Increased
23
Reduced
22
Closed
5
Top Buys
| 1 |
Murphy USA
MUSA
|
+$2.24M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$421K |
| 3 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$347K |
| 4 |
JPMorgan Chase
JPM
|
+$194K |
| 5 |
ASG
Liberty All-Star Growth Fund
ASG
|
+$118K |
Top Sells
| 1 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$5.85M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$3.91M |
| 3 |
Amazon
AMZN
|
+$3.29M |
| 4 |
Dollar Tree
DLTR
|
+$2.61M |
| 5 |
eBay
EBAY
|
+$1.76M |
Sector Composition
| 1 | Healthcare | 17.01% |
| 2 | Technology | 16.14% |
| 3 | Financials | 5.4% |
| 4 | Consumer Discretionary | 4.24% |
| 5 | Utilities | 2.42% |
Similar funds
SFB
KG
CWWM
SM
AWP
PC
CH
VF
David J. Yvars Group's Q4 2022 Portfolio in Review
As of Q4 2022, David J. Yvars Group held 71 positions worth $79.8M, down 11% from $90M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
David J. Yvars Group withdrew a net $16M in Q4 2022, closing 5 positions and reducing 22 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $3.91M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 17% a quarter earlier, followed by Technology and Financials.
Against the trend, David J. Yvars Group opened a new position in Murphy USA worth $2.16M.
- David J. Yvars Group's largest Q4 2022 buy was Murphy USA: 7,710 shares worth $2.16M.
- David J. Yvars Group added most to iShares Core S&P 500 ETF in Q4 2022, an estimated $421K increase.
- David J. Yvars Group's biggest Q4 2022 reduction was State Street Technology Select Sector SPDR ETF, cutting an estimated $5.85M.
- David J. Yvars Group fully exited Vertex Pharmaceuticals in Q4 2022, selling an estimated $3.91M.
- David J. Yvars Group's ten largest holdings make up 66% of its $79.8M portfolio in Q4 2022.
- David J. Yvars Group opened 5 new positions and closed 5 in Q4 2022.
- David J. Yvars Group's portfolio value fell 11% quarter-over-quarter to $79.8M.
Based on David J. Yvars Group's 13F filing for Q4 2022, filed 18 Jan 2023.